Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Axsome Therapeutics (AXSM) Shares Outstanding (Weighted Average): 2015-2024

Historic Shares Outstanding (Weighted Average) for Axsome Therapeutics (AXSM) over the last 10 years, with Dec 2024 value amounting to $48.5 million.

  • Axsome Therapeutics' Shares Outstanding (Weighted Average) rose 3.96% to $49.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $49.9 million, marking a year-over-year increase of 3.96%. This contributed to the annual value of $48.5 million for FY2024, which is 2.42% up from last year.
  • As of FY2024, Axsome Therapeutics' Shares Outstanding (Weighted Average) stood at $48.5 million, which was up 2.42% from $47.3 million recorded in FY2023.
  • Over the past 5 years, Axsome Therapeutics' Shares Outstanding (Weighted Average) peaked at $48.5 million during FY2024, and registered a low of $37.3 million during FY2020.
  • Its 3-year average for Shares Outstanding (Weighted Average) is $46.4 million, with a median of $47.3 million in 2023.
  • Data for Axsome Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY rose of 15.21% (in 2022) over the last 5 years.
  • Over the past 5 years, Axsome Therapeutics' Shares Outstanding (Weighted Average) (Yearly) stood at $37.3 million in 2020, then climbed by 0.93% to $37.7 million in 2021, then increased by 15.21% to $43.4 million in 2022, then rose by 8.97% to $47.3 million in 2023, then rose by 2.42% to $48.5 million in 2024.